2Poole-wilson PA,Lubsen J,Kirwan BA,et al.A Coronary disease Trial lnvestigating Outcome with Nifedipine gastrointestinal therapeutic system investigators.Effect Of long-acting nifedipine On mortality and cardiovascular morbidity in patients with stable angina requiring treatment(ACTION trial):randomised controlled trial[J].Lancet,2004,364(9437):849-857.
3Nissen SE,Tuzcu EM,Libby P,et al.Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure.The CAMELOTstudy:a randomized controlled trial[J].JAMA,2004,292(18):2217-2225.
4Lin-lee YC,Tanaka Y,Lin CT,et al.Effects of an atherogenic diet on apolipoprotein E biosynthesis in the rat[J].Biochemistry,1981,20(22):6474-6480.
5Soma MR,Natali M,Donetti E,et al.Effect of lercanidipine and its(R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits[J].Br J Pharmacol,l998,l25(7):l47l-1476.
6Corsini A,Accomazzo MR,Canavesi M,et al.The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro:is calcium entry involved?[J].Blood Press suppl,1998,2(1):l8-22.
7Dhein S,Salameh A,Berkels R,et al.Dual mode of action of dihydropyridine calcium antagonists:a role for nitric oxide[J].Drugs,1999,58(3):397-404.
8Cromheeke KM,Kockx MM,Demeyer GR,et al.Inducible nitric oxide synthase colocalizes with signs of lipid oxidation/peroxidation in human atherosclerotic plaques[J].Cardiovasc Res,1999,43(3):744-754.
9Detmers PA,Hernandez M,Mudgett J,et al.Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice[J].J Immunol,2000,165(6):3430-3435.
10Chou TC,Yang SP,Pei D.Amlodipine inhibits pro-inflammatory cytokines and free radical production and inducible nitric oxide synthase expression in lipopolysaccharide/interferon-gamma-stimulated cultured vascular smooth muscle cells[J].Jpn J Pharmacol,2002,89(2):157-163.
